ANI Pharmaceuticals (ANIP) FY2014 results: revenue $56 million, up 86.1% on the year
ANI Pharmaceuticals Inc. (ANIP) reported revenue of $56 million for fiscal 2014, the year ended 31 December 2014, up 86.1% on the year before. Net income was $29 million, up 9450.5%, and diluted earnings per share $2.59. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2015.
Revenue
$56 million
+86.1% on the year
FY2009FY2014
Operating margin
35.7%
3.0% a year earlier
FY2009FY2014
Net income
$29 million
+9,450.5% on the year
FY2009FY2014
Diluted EPS
$2.59
FY2009FY2014
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Revenue
56.0
30.1
20.4
+86.1%
Cost of revenue
11.5
10.0
9.2
+15.0%
Gross profit
44.5
20.1
11.2
+121.3%
Gross margin
79.5%
66.8%
55.0%
Research and development
2.7
1.7
1.2
+56.4%
Selling, general and administrative
17.9
16.4
9.5
+9.4%
Operating income
20.0
0.9
-0.0
+2,127.8%
Operating margin
35.7%
3.0%
-0.2%
Interest expense
0.8
0.5
1.3
+73.7%
Pre-tax income
19.4
0.1
-1.6
+15,280.2%
Income tax
-9.4
0.0
-0.0
Effective tax rate
-48.3%
15.9%
n/a
Net income
28.7
0.3
-1.5
+9,450.5%
Net margin
51.4%
1.0%
-7.4%
Diluted EPS
$2.59
-$0.92
-$1.27
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Operating cash flow
22.0
-5.5
-0.1
Capital expenditure
1.1
0.2
0.3
+486.4%
Free cash flow
20.9
-5.7
-0.4
Free cash flow margin
37.4%
-18.9%
-2.1%
Cash from investing
-35.8
n/a
n/a
Cash from financing
172
-3.7
0.4
Depreciation and amortisation
3.9
1.1
0.6
+249.4%
Share-based compensation
3.4
0.0
0.0
+9,408.3%
Buybacks
0.0
0.4
0.0
Diluted shares, weighted
11m
5m
22m
+118.0%
Balance sheet
$ million
FY2014
FY2013
FY2012
On the year
Last 8 years
Shareholders' equity
140
41.0
-42.7
+241.3%
Debt
107
0.0
4.1
Other liabilities
13.2
3.5
52.4
+274.0%
Total liabilities and equity
260
44.5
13.7
+483.3%
Fixed assets
5.2
4.5
4.9
+15.1%
Goodwill
1.8
1.8
0.0
0.0%
Intangible assets
42.1
10.4
0.1
+304.1%
Investments
n/a
n/a
3.4
Cash and equivalents
169
11.1
0.0
+1,422.2%
Receivables
17.3
12.5
5.4
+38.2%
Inventory
7.5
3.5
2.8
+113.7%
Other assets
16.6
0.6
n/a
+2,758.3%
Total assets
260
44.5
13.7
+483.3%
10-K for the year ended 31 December 2014, filed 23 February 2015: the filing.